[{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04877522"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":4,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EA06"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":4,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02690922"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02389920"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04877522"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":4,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02602314"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001378","diseaseName":"multiple myeloma","phase":4,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05944783"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04874207"]},{"drugId":"CHEMBL2095206","drugName":"BOSUTINIB MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3","https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00510354","https://clinicaltrials.gov/study/NCT00171977"]},{"drugId":"CHEMBL2095206","drugName":"BOSUTINIB MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001642","diseaseName":"lymphoid neoplasm","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03844360"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02317159"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04877522"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01131325","https://clinicaltrials.gov/study/NCT02086487"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03216070"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01660906","https://clinicaltrials.gov/study/NCT04925141"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":4,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EA02"]},{"drugId":"CHEMBL4297220","drugName":"ASCIMINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":4,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00756509"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02204722"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01605981"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":4,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01742299"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00171977","https://clinicaltrials.gov/study/NCT00510354"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00786812","https://clinicaltrials.gov/study/NCT03332511","https://clinicaltrials.gov/study/NCT01368523","https://clinicaltrials.gov/study/NCT02546674","https://clinicaltrials.gov/study/NCT01061177","https://clinicaltrials.gov/study/NCT01227577","https://clinicaltrials.gov/study/NCT00980018","https://clinicaltrials.gov/study/NCT01043874","https://clinicaltrials.gov/study/NCT01206088"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000630","diseaseName":"marginal zone B-cell lymphoma","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04877522"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04155411","https://clinicaltrials.gov/study/NCT04877522","https://clinicaltrials.gov/study/NCT04933526"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":4,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02602314"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7"]},{"drugId":"CHEMBL4297220","drugName":"ASCIMINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf"]},{"drugId":"CHEMBL3545413","drugName":"FLUMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05367765"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":4,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01742299"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cdecefe-c9e4-4af3-bbaa-a1111c768d29"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05367765"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cdecefe-c9e4-4af3-bbaa-a1111c768d29"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000630","diseaseName":"marginal zone B-cell lymphoma","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":4,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EX25"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02228382"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0016586","diseaseName":"systemic mastocytosis","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01297777"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05071482"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001642","diseaseName":"lymphoid neoplasm","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03844360"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00845221","https://clinicaltrials.gov/study/NCT00081926","https://clinicaltrials.gov/study/NCT00390897","https://clinicaltrials.gov/study/NCT01578213","https://clinicaltrials.gov/study/NCT00171899"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71"]},{"drugId":"CHEMBL3545413","drugName":"FLUMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04933526","https://clinicaltrials.gov/study/NCT04677439","https://clinicaltrials.gov/study/NCT05353205"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03564938"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0016586","diseaseName":"systemic mastocytosis","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01297777"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01578213","https://clinicaltrials.gov/study/NCT00171899","https://clinicaltrials.gov/study/NCT00081926","https://clinicaltrials.gov/study/NCT00390897","https://clinicaltrials.gov/study/NCT00845221"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":4,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00372476"]},{"drugId":"CHEMBL3545413","drugName":"FLUMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05071482"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":4,"status":null,"source":["https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":4,"status":null,"source":["https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":4,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02894645","https://clinicaltrials.gov/study/NCT01491763"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":4,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EX05"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001814","diseaseName":"nephrogenic fibrosing dermopathy","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00981942"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01650805","https://clinicaltrials.gov/study/NCT02627677"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02612311"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02664077"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01271712","https://clinicaltrials.gov/study/NCT03465722"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04948333","https://clinicaltrials.gov/study/NCT04971226","https://clinicaltrials.gov/study/NCT03106779","https://clinicaltrials.gov/study/NCT04666259"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00154375"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00154375"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05311943"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT05328908","https://clinicaltrials.gov/study/NCT04776148"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003106","diseaseName":"pneumonia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02735707"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03117751","https://clinicaltrials.gov/study/NCT02883049","https://clinicaltrials.gov/study/NCT03020030"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00327678"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00327678"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02413736"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00362466"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01254188","https://clinicaltrials.gov/study/NCT01126892","https://clinicaltrials.gov/study/NCT01535391","https://clinicaltrials.gov/study/NCT00760877","https://clinicaltrials.gov/study/NCT00471497","https://clinicaltrials.gov/study/NCT00802841","https://clinicaltrials.gov/study/NCT01275196","https://clinicaltrials.gov/study/NCT01743989","https://clinicaltrials.gov/study/NCT01819389"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT05064059","https://clinicaltrials.gov/study/NCT05600309"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02612311"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00116935","https://clinicaltrials.gov/study/NCT00367861"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03079505"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0100096","diseaseName":"COVID-19","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02735707"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01400074","https://clinicaltrials.gov/study/NCT02201459"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":3,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EA05"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006343","https://clinicaltrials.gov/study/NCT00002514","https://clinicaltrials.gov/study/NCT00055874"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000870","diseaseName":"childhood acute lymphoblastic leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00022737"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02788279"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02611492"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00362466"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000272","diseaseName":"astrocytoma","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00154375"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":3,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01786538"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007576","diseaseName":"esophageal cancer","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02773524"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06051409"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00718263","https://clinicaltrials.gov/study/NCT04971226"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000673","diseaseName":"prostate adenocarcinoma","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00744497"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006343","https://clinicaltrials.gov/study/NCT00002514","https://clinicaltrials.gov/study/NCT00055874","https://clinicaltrials.gov/study/NCT02272777"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03079505"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03801525"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":3,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EA01"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06124157"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00519090"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03106779","https://clinicaltrials.gov/study/NCT04971226"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04530565"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01827930","https://clinicaltrials.gov/study/NCT00124748"]},{"drugId":"CHEMBL3545413","drugName":"FLUMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04375683"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02326311"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01827930","https://clinicaltrials.gov/study/NCT02174445","https://clinicaltrials.gov/study/NCT01650805","https://clinicaltrials.gov/study/NCT00124748"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001968","diseaseName":"soft tissue sarcoma","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03784014"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05143528"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001073","diseaseName":"obesity","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05653258"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05456191","https://clinicaltrials.gov/study/NCT05413915"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01103323"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT04985136"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05794971","https://clinicaltrials.gov/study/NCT03829462","https://clinicaltrials.gov/study/NCT05462613"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0001606","diseaseName":"central nervous system leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02883049"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01460693","https://clinicaltrials.gov/study/NCT00123487","https://clinicaltrials.gov/study/NCT00123474","https://clinicaltrials.gov/study/NCT00481247","https://clinicaltrials.gov/study/NCT02890784"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00137111"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00519090"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02272777"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02013648"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03020030"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04530565"]},{"drugId":"CHEMBL4297524","drugName":"RADOTINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03459534"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000272","diseaseName":"astrocytoma","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00154375"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01400074"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0100096","diseaseName":"COVID-19","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04394416","https://clinicaltrials.gov/study/NCT04330690"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000209","diseaseName":"T-cell acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03007147"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00574873","https://clinicaltrials.gov/study/NCT02130557"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00293124","https://clinicaltrials.gov/study/NCT00367861","https://clinicaltrials.gov/study/NCT00041197","https://clinicaltrials.gov/study/NCT00471328","https://clinicaltrials.gov/study/NCT00785785","https://clinicaltrials.gov/study/NCT00103168","https://clinicaltrials.gov/study/NCT02260505","https://clinicaltrials.gov/study/NCT01151852"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04530565"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01774344"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00297570","https://clinicaltrials.gov/study/NCT01400074","https://clinicaltrials.gov/study/NCT00327262","https://clinicaltrials.gov/study/NCT03515018"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00956072","https://clinicaltrials.gov/study/NCT00372567","https://clinicaltrials.gov/study/NCT00324987","https://clinicaltrials.gov/study/NCT00751036","https://clinicaltrials.gov/study/NCT00009906","https://clinicaltrials.gov/study/NCT01031628","https://clinicaltrials.gov/study/NCT00812240"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000712","diseaseName":"stroke","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03639922"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02042014","https://clinicaltrials.gov/study/NCT00902174"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04722848"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04777851"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03589326"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00751036"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04971226"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02611492"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03942094","https://clinicaltrials.gov/study/NCT02326311","https://clinicaltrials.gov/study/NCT05456191"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0020743","diseaseName":"mixed phenotype acute leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03007147"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0007328","diseaseName":"influenza","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02735707"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":3,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EA03"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01392495","https://clinicaltrials.gov/study/NCT01117987"]},{"drugId":"CHEMBL3678958","drugName":"RUSERONTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04716114"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00549848","https://clinicaltrials.gov/study/NCT00123487"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04307576","https://clinicaltrials.gov/study/NCT04722848","https://clinicaltrials.gov/study/NCT06051409"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001814","diseaseName":"nephrogenic fibrosing dermopathy","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00981942"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00471328","https://clinicaltrials.gov/study/NCT00785785","https://clinicaltrials.gov/study/NCT01289028"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00009906","https://clinicaltrials.gov/study/NCT00324987","https://clinicaltrials.gov/study/NCT01031628","https://clinicaltrials.gov/study/NCT00956072","https://clinicaltrials.gov/study/NCT00372567"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00718263","https://clinicaltrials.gov/study/NCT03722420","https://clinicaltrials.gov/study/NCT04971226"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0020743","diseaseName":"mixed phenotype acute leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03007147"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00685828"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02934529"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00685828"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00219739","https://clinicaltrials.gov/study/NCT01460693","https://clinicaltrials.gov/study/NCT00481247","https://clinicaltrials.gov/study/NCT01819389","https://clinicaltrials.gov/study/NCT00471497","https://clinicaltrials.gov/study/NCT00514488","https://clinicaltrials.gov/study/NCT02130557","https://clinicaltrials.gov/study/NCT00237120","https://clinicaltrials.gov/study/NCT00760877","https://clinicaltrials.gov/study/NCT00802841","https://clinicaltrials.gov/study/NCT00050531","https://clinicaltrials.gov/study/NCT01275196","https://clinicaltrials.gov/study/NCT00333840","https://clinicaltrials.gov/study/NCT00574873","https://clinicaltrials.gov/study/NCT02204644"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02174445","https://clinicaltrials.gov/study/NCT02108951","https://clinicaltrials.gov/study/NCT03079505","https://clinicaltrials.gov/study/NCT02115386","https://clinicaltrials.gov/study/NCT02627677"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03970447"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01939223"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT05198934"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02326311","https://clinicaltrials.gov/study/NCT05413915"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00116935","https://clinicaltrials.gov/study/NCT00367861"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000873","diseaseName":"lymphoblastic lymphoma","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02881086"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05425940"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00103168","https://clinicaltrials.gov/study/NCT00293124","https://clinicaltrials.gov/study/NCT00041197","https://clinicaltrials.gov/study/NCT00367861"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01392469","https://clinicaltrials.gov/study/NCT02042014","https://clinicaltrials.gov/study/NCT00902174"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007576","diseaseName":"esophageal cancer","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04879368"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00050531","https://clinicaltrials.gov/study/NCT00219739","https://clinicaltrials.gov/study/NCT00514488","https://clinicaltrials.gov/study/NCT02204644"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":3,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=L01EA04"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000209","diseaseName":"T-cell acute lymphoblastic leukemia","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03007147"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03589326","https://clinicaltrials.gov/study/NCT02881086"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000870","diseaseName":"childhood acute lymphoblastic leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00022737"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0013730","diseaseName":"graft versus host disease","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03112603"]},{"drugId":"CHEMBL4297524","drugName":"RADOTINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03722420"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01584830"]},{"drugId":"CHEMBL3545413","drugName":"FLUMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02204644"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01570868"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000389","diseaseName":"cutaneous melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00700882"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003060","diseaseName":"biliary tract cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04781192","https://clinicaltrials.gov/study/NCT05820906"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"HP_0009588","diseaseName":"Vestibular schwannoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01201538"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000096","diseaseName":"neoplasm of mature B-cells","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02793583"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00684411"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00904735"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001993","diseaseName":"scleroderma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01545427"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00080678","https://clinicaltrials.gov/study/NCT00084825","https://clinicaltrials.gov/study/NCT00500110","https://clinicaltrials.gov/study/NCT00427999","https://clinicaltrials.gov/study/NCT00251225"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06055621"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03874858","https://clinicaltrials.gov/study/NCT04795427","https://clinicaltrials.gov/study/NCT03906292","https://clinicaltrials.gov/study/NCT04216563"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001378","diseaseName":"multiple myeloma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00429949"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00904735"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03205267"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018364","diseaseName":"malignant epithelial tumor of ovary","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00036751"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02810990","https://clinicaltrials.gov/study/NCT03128411","https://clinicaltrials.gov/study/NCT02269267","https://clinicaltrials.gov/study/NCT00261846","https://clinicaltrials.gov/study/NCT00811070","https://clinicaltrials.gov/study/NCT02311998"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002618","diseaseName":"undifferentiated high grade pleomorphic sarcoma of bone","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00031915"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06061094"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01166139"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00504153"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000475","diseaseName":"Pineoblastoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02596828"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0100096","diseaseName":"COVID-19","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04488081"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000621","diseaseName":"neuroblastoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01467986"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00568750"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00476190"]},{"drugId":"CHEMBL1738757","drugName":"REBASTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03601897","https://clinicaltrials.gov/study/NCT03717415"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00171938"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001465","diseaseName":"gliosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00354913","https://clinicaltrials.gov/study/NCT00615927"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0020634","diseaseName":"grade III meningioma","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06275919"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000437","diseaseName":"cerebellar ataxia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03932669"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000251","diseaseName":"Fallopian Tube Carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0020547","diseaseName":"chronic graft versus host disease","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01898377"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00068380"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000389","diseaseName":"cutaneous melanoma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01168050"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001075","diseaseName":"ovarian carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00638937"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05113368"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03654768","https://clinicaltrials.gov/study/NCT00070499","https://clinicaltrials.gov/study/NCT03193281","https://clinicaltrials.gov/study/NCT04070443","https://clinicaltrials.gov/study/NCT04578847","https://clinicaltrials.gov/study/NCT04147533","https://clinicaltrials.gov/study/NCT04126681","https://clinicaltrials.gov/study/NCT03906292","https://clinicaltrials.gov/study/NCT02852486"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000702","diseaseName":"small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00470054"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01528085"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001361","diseaseName":"localised scleroderma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00479934"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02096354","https://clinicaltrials.gov/study/NCT02465502","https://clinicaltrials.gov/study/NCT01289821","https://clinicaltrials.gov/study/NCT02195011"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00323063"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0024880","diseaseName":"metastatic malignant neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00410813"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0016586","diseaseName":"systemic mastocytosis","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00979160"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT04554459"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015686","diseaseName":"primary peritoneal carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018975","diseaseName":"neurofibromatosis type 1","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01673009"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00338728","https://clinicaltrials.gov/study/NCT00087152"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001949","diseaseName":"colon adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02368886"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01166139"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02501551"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000180","diseaseName":"HIV-1 infection","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05527418"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06336395"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002516","diseaseName":"digestive system cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06099821"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015686","diseaseName":"primary peritoneal carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00928642"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01331291"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009907","diseaseName":"Desmoid-type fibromatosis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01137916","https://clinicaltrials.gov/study/NCT00928525"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0000873","diseaseName":"lymphoblastic lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023046"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0100096","diseaseName":"COVID-19","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04488081"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04806243","https://clinicaltrials.gov/study/NCT05962450","https://clinicaltrials.gov/study/NCT05917431","https://clinicaltrials.gov/study/NCT05770882","https://clinicaltrials.gov/study/NCT05048017","https://clinicaltrials.gov/study/NCT03899428","https://clinicaltrials.gov/study/NCT05622136","https://clinicaltrials.gov/study/NCT05194293","https://clinicaltrials.gov/study/NCT04183088"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001075","diseaseName":"ovarian carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02584465"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000621","diseaseName":"neuroblastoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02559778"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0022597","diseaseName":"aging","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT05422885"]},{"drugId":"CHEMBL2095206","drugName":"BOSUTINIB MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03205267"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039377"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01312818"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000044","diseaseName":"pancreatic adenocarcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02383433"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001993","diseaseName":"scleroderma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01545427"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000403","diseaseName":"diffuse large B-cell lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02874404"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00499889","https://clinicaltrials.gov/study/NCT01005914","https://clinicaltrials.gov/study/NCT00015847","https://clinicaltrials.gov/study/NCT00882206","https://clinicaltrials.gov/study/NCT00022490"]},{"drugId":"CHEMBL3545413","drugName":"FLUMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02511340","https://clinicaltrials.gov/study/NCT01503502"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT04709731"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000403","diseaseName":"diffuse large B-cell lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02874404"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0022597","diseaseName":"aging","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04946383"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000574","diseaseName":"lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00882206"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003841","diseaseName":"thyroid neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01838642"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02288078"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT04423185"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00459342"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00027586"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03178201"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00015847","https://clinicaltrials.gov/study/NCT00022490","https://clinicaltrials.gov/study/NCT00415857","https://clinicaltrials.gov/study/NCT00882206","https://clinicaltrials.gov/study/NCT00499889","https://clinicaltrials.gov/study/NCT01005914"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT05554341"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000544","diseaseName":"mucosal melanoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00424515"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02365441"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011934","diseaseName":"dermatofibrosarcoma protuberans","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00084630","https://clinicaltrials.gov/study/NCT00243191"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01471106"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02402036"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03844620","https://clinicaltrials.gov/study/NCT03377361"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000702","diseaseName":"small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00052949","https://clinicaltrials.gov/study/NCT00156286"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003869","diseaseName":"breast neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02720185"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04416750"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039364"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003897","diseaseName":"stomach neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03170180"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001465","diseaseName":"gliosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00423735"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009441","diseaseName":"Waldenstrom macroglobulinemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03364231"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000673","diseaseName":"prostate adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01316458"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00159016"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0024686","diseaseName":"tenosynovial giant cell tumor, diffuse type","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01261429"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002617","diseaseName":"metastatic melanoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00402662"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT04508647"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001968","diseaseName":"soft tissue sarcoma","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT03793361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0100342","diseaseName":"malignant glioma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03352427"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0044917","diseaseName":"T-lymphoblastic lymphoma","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02538926"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002428","diseaseName":"chronic myeloproliferative disorder","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00245128"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001465","diseaseName":"gliosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00615927","https://clinicaltrials.gov/study/NCT00354913"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005147","diseaseName":"type 1 diabetes mellitus","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01781975"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000760","diseaseName":"malignant peripheral nerve sheath tumor","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00427583"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001469","diseaseName":"Mantle cell lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT04692155"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000313","diseaseName":"carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01153750"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00397878"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000768","diseaseName":"idiopathic pulmonary fibrosis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00131274"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02687425","https://clinicaltrials.gov/study/NCT01221376","https://clinicaltrials.gov/study/NCT03241199","https://clinicaltrials.gov/study/NCT00146913"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00551252"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000658","diseaseName":"plexiform neurofibroma","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT03688568"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000574","diseaseName":"lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00364286"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00216112","https://clinicaltrials.gov/study/NCT00039585","https://clinicaltrials.gov/study/NCT00510653","https://clinicaltrials.gov/study/NCT00928642"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT04688983"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04043676","https://clinicaltrials.gov/study/NCT01746836"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00385580","https://clinicaltrials.gov/study/NCT01254864","https://clinicaltrials.gov/study/NCT01260688","https://clinicaltrials.gov/study/NCT00570700"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00564876","https://clinicaltrials.gov/study/NCT00787267","https://clinicaltrials.gov/study/NCT01514864"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT04845035"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000658","diseaseName":"plexiform neurofibroma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02177825"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00424515"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002158","diseaseName":"fallopian tube cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039585"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT01222013"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0003175","diseaseName":"salivary gland adenoid cystic carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00859937"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003833","diseaseName":"brain neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00423735"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04126681","https://clinicaltrials.gov/study/NCT03883100","https://clinicaltrials.gov/study/NCT03883087"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03377361","https://clinicaltrials.gov/study/NCT02619435"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01771458"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02651415","https://clinicaltrials.gov/study/NCT02835924","https://clinicaltrials.gov/study/NCT02466009","https://clinicaltrials.gov/study/NCT01298570","https://clinicaltrials.gov/study/NCT02699073","https://clinicaltrials.gov/study/NCT03898102"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000403","diseaseName":"diffuse large B-cell lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02793583"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001951","diseaseName":"colorectal carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05382741"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00615927"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000658","diseaseName":"plexiform neurofibroma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02177825"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000403","diseaseName":"diffuse large B-cell lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00918463"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04624633"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02303899"]},{"drugId":"CHEMBL495727","drugName":"AT-9283","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001378","diseaseName":"multiple myeloma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01145989"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00744081"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001378","diseaseName":"multiple myeloma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01116128"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005147","diseaseName":"type 1 diabetes mellitus","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01781975"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01991379"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02316340","https://clinicaltrials.gov/study/NCT04126733"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001467","diseaseName":"Hypereosinophilic syndrome","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00171860","https://clinicaltrials.gov/study/NCT00230334"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00594555"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004979","diseaseName":"asthma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01097694"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT05730673","https://clinicaltrials.gov/study/NCT05900648"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001512","diseaseName":"endometrial carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00265876"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00290485"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0024880","diseaseName":"metastatic malignant neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00084825","https://clinicaltrials.gov/study/NCT00080678"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003865","diseaseName":"acral lentiginous melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00470470"]},{"drugId":"CHEMBL206834","drugName":"BAFETINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01215799"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0005537","diseaseName":"triple-negative breast cancer","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06355037"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001968","diseaseName":"soft tissue sarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02048722"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05385549","https://clinicaltrials.gov/study/NCT05152472","https://clinicaltrials.gov/study/NCT04933669","https://clinicaltrials.gov/study/NCT05009927","https://clinicaltrials.gov/study/NCT05493215","https://clinicaltrials.gov/study/NCT02924714"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000637","diseaseName":"osteosarcoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00752206"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00481052","https://clinicaltrials.gov/study/NCT01294618","https://clinicaltrials.gov/study/NCT00129740","https://clinicaltrials.gov/study/NCT02353728","https://clinicaltrials.gov/study/NCT02269267","https://clinicaltrials.gov/study/NCT01856283","https://clinicaltrials.gov/study/NCT01844765","https://clinicaltrials.gov/study/NCT01274351","https://clinicaltrials.gov/study/NCT00264160","https://clinicaltrials.gov/study/NCT01774630","https://clinicaltrials.gov/study/NCT01744665"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00112775"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02278783"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002158","diseaseName":"fallopian tube cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02278783"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00858403"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04626024","https://clinicaltrials.gov/study/NCT03831776"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001951","diseaseName":"colorectal carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02119676"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0005221","diseaseName":"cholangiocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02428855"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00513071"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04626024"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009606","diseaseName":"macular degeneration","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02222207"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01990196"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00101816","https://clinicaltrials.gov/study/NCT00103844","https://clinicaltrials.gov/study/NCT01593254","https://clinicaltrials.gov/study/NCT00866736","https://clinicaltrials.gov/study/NCT03625388","https://clinicaltrials.gov/study/NCT01872442","https://clinicaltrials.gov/study/NCT01725204","https://clinicaltrials.gov/study/NCT01850004","https://clinicaltrials.gov/study/NCT02269267","https://clinicaltrials.gov/study/NCT01342679","https://clinicaltrials.gov/study/NCT00852566","https://clinicaltrials.gov/study/NCT01916785","https://clinicaltrials.gov/study/NCT00101660","https://clinicaltrials.gov/study/NCT00101647"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007606","diseaseName":"fibrodysplasia ossificans progressiva","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04307953"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05931757","https://clinicaltrials.gov/study/NCT05466175"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05274438","https://clinicaltrials.gov/study/NCT04546074","https://clinicaltrials.gov/study/NCT04598009"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001467","diseaseName":"Hypereosinophilic syndrome","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00171860","https://clinicaltrials.gov/study/NCT00230334"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002367","diseaseName":"kidney cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00331409"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001471","diseaseName":"Merkel cell skin cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00068783"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03994601"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02311998"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00669019"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03880877","https://clinicaltrials.gov/study/NCT05963490","https://clinicaltrials.gov/study/NCT04030260","https://clinicaltrials.gov/study/NCT05485909","https://clinicaltrials.gov/study/NCT05970705","https://clinicaltrials.gov/study/NCT05877001"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01949194"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000231","diseaseName":"adenoid cystic carcinoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02098538"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02445742","https://clinicaltrials.gov/study/NCT02638467"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001496","diseaseName":"Autosomal dominant polycystic kidney disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01233869"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001951","diseaseName":"colorectal carcinoma","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06006923"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000503","diseaseName":"gastric adenocarcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00209079"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0006859","diseaseName":"head and neck malignant neoplasia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00045669"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01189903"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002108","diseaseName":"thyroid cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00115739"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00718562","https://clinicaltrials.gov/study/NCT01863745","https://clinicaltrials.gov/study/NCT00633295","https://clinicaltrials.gov/study/NCT01110668"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03828448","https://clinicaltrials.gov/study/NCT03178201","https://clinicaltrials.gov/study/NCT02793583"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01441882","https://clinicaltrials.gov/study/NCT00438854"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000044","diseaseName":"pancreatic adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00474812"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000702","diseaseName":"small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00156286","https://clinicaltrials.gov/study/NCT00052949"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00550615"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002429","diseaseName":"polycythemia vera","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00538980"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005301","diseaseName":"multiple sclerosis","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03674099"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00421317"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02744768"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01011075","https://clinicaltrials.gov/study/NCT01083589"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00793546","https://clinicaltrials.gov/study/NCT00880009"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005180","diseaseName":"Parkinson disease","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02954978"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002617","diseaseName":"metastatic melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01099514"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00180830"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00159016"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000613","diseaseName":"Uterine Carcinosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00075400"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000708","diseaseName":"squamous cell lung carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01491633"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000305","diseaseName":"breast carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT05198843"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004288","diseaseName":"colonic neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02685046"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01991379","https://clinicaltrials.gov/study/NCT02365441","https://clinicaltrials.gov/study/NCT01541709"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05036226"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04757363"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03171389"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02776605"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05143840","https://clinicaltrials.gov/study/NCT04626024","https://clinicaltrials.gov/study/NCT04838041"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001075","diseaseName":"ovarian carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00436605"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00041340"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001467","diseaseName":"Hypereosinophilic syndrome","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT00044304"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008978","diseaseName":"chordoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00150072"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00615927"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000581","diseaseName":"Thymoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00718809"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039364"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04925479","https://clinicaltrials.gov/study/NCT05143840","https://clinicaltrials.gov/study/NCT06236724","https://clinicaltrials.gov/study/NCT05384587"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01092728"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003884","diseaseName":"chronic kidney disease","phase":2,"status":"Enrolling by invitation","source":["https://clinicaltrials.gov/study/NCT02848131"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02523976","https://clinicaltrials.gov/study/NCT01441882"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02638428"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000026","diseaseName":"diffuse intrinsic pontine glioma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02233049"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018364","diseaseName":"malignant epithelial tumor of ovary","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00036751"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03654768","https://clinicaltrials.gov/study/NCT04258943","https://clinicaltrials.gov/study/NCT04578847"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002367","diseaseName":"kidney cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00331409"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00744081","https://clinicaltrials.gov/study/NCT00707408"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00070499"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04838041","https://clinicaltrials.gov/study/NCT04626024"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000873","diseaseName":"lymphoblastic lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023046"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06087263"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00509041"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000729","diseaseName":"loiasis","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02644525"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00041340"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003060","diseaseName":"biliary tract cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02053376"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00154349","https://clinicaltrials.gov/study/NCT00388895","https://clinicaltrials.gov/study/NCT03023046"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000673","diseaseName":"prostate adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00570700"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04329325"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT04688983"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00210119","https://clinicaltrials.gov/study/NCT00038649","https://clinicaltrials.gov/study/NCT02709083","https://clinicaltrials.gov/study/NCT00415909","https://clinicaltrials.gov/study/NCT00114959"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005180","diseaseName":"Parkinson disease","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02954978"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00180830"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000613","diseaseName":"Uterine Carcinosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00075400"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01357655"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000571","diseaseName":"lung adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01935336"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002367","diseaseName":"kidney cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00323791"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002618","diseaseName":"undifferentiated high grade pleomorphic sarcoma of bone","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00031915"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05376852"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002429","diseaseName":"polycythemia vera","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00430066","https://clinicaltrials.gov/study/NCT01120821"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00068380"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02661113"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002626","diseaseName":"thymus neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00718809"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000251","diseaseName":"Fallopian Tube Carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0100096","diseaseName":"COVID-19","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT04830735"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00613171","https://clinicaltrials.gov/study/NCT00479934","https://clinicaltrials.gov/study/NCT00555581"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001469","diseaseName":"Mantle cell lymphoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04783415"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00777036"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00477269"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00091078"]},{"drugId":"CHEMBL4297524","drugName":"RADOTINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02422719"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00573326"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002429","diseaseName":"polycythemia vera","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01120821","https://clinicaltrials.gov/study/NCT00430066"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT01746836"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000681","diseaseName":"renal cell carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00664326"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00091078"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01011998","https://clinicaltrials.gov/study/NCT00594555"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000333","diseaseName":"chondrosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00928525"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT04476329"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002428","diseaseName":"chronic myeloproliferative disorder","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00245128"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0006861","diseaseName":"male breast carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00045188"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01806571"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0044743","diseaseName":"major salivary gland cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00859937"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03627728"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02024607"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000313","diseaseName":"carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01153750"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04747912","https://clinicaltrials.gov/study/NCT05192889","https://clinicaltrials.gov/study/NCT03564470"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00973752","https://clinicaltrials.gov/study/NCT00376467","https://clinicaltrials.gov/study/NCT00130195","https://clinicaltrials.gov/study/NCT00388895","https://clinicaltrials.gov/study/NCT00154349","https://clinicaltrials.gov/study/NCT03023046","https://clinicaltrials.gov/study/NCT00287105"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06280105"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT04016805","https://clinicaltrials.gov/study/NCT03207256","https://clinicaltrials.gov/study/NCT04163718","https://clinicaltrials.gov/study/NCT02656303","https://clinicaltrials.gov/study/NCT04149821","https://clinicaltrials.gov/study/NCT03828448"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0044919","diseaseName":"malignant renal pelvis neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02459119"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003865","diseaseName":"acral lentiginous melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00470470"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05366816"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0020690","diseaseName":"adult glioblastoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00423735"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0000873","diseaseName":"lymphoblastic lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02043587"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02368886"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004329","diseaseName":"alcohol drinking","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02955186"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002108","diseaseName":"thyroid cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02657551"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05985109","https://clinicaltrials.gov/study/NCT04787341"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT04845035"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00041340"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0044917","diseaseName":"T-lymphoblastic lymphoma","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02538926"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01460160","https://clinicaltrials.gov/study/NCT00364286","https://clinicaltrials.gov/study/NCT00982488","https://clinicaltrials.gov/study/NCT00529763"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01005758","https://clinicaltrials.gov/study/NCT00112775","https://clinicaltrials.gov/study/NCT01227135"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000218","diseaseName":"Digestive System Carcinoma","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01270893"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000196","diseaseName":"metastatic prostate cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04925648"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002617","diseaseName":"metastatic melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01876212"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000569","diseaseName":"liposarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02048371"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05274438","https://clinicaltrials.gov/study/NCT04546074"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02461849"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02398825"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04503694"]},{"drugId":"CHEMBL4297524","drugName":"RADOTINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005180","diseaseName":"Parkinson disease","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04691661"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01172548","https://clinicaltrials.gov/study/NCT00867113","https://clinicaltrials.gov/study/NCT01483014","https://clinicaltrials.gov/study/NCT00940563","https://clinicaltrials.gov/study/NCT00112632","https://clinicaltrials.gov/study/NCT00237185","https://clinicaltrials.gov/study/NCT00500188","https://clinicaltrials.gov/study/NCT00028002","https://clinicaltrials.gov/study/NCT00455559","https://clinicaltrials.gov/study/NCT00025246","https://clinicaltrials.gov/study/NCT02712112","https://clinicaltrials.gov/study/NCT01267695","https://clinicaltrials.gov/study/NCT00237172","https://clinicaltrials.gov/study/NCT01294202"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009907","diseaseName":"Desmoid-type fibromatosis","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03802084"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021637","diseaseName":"low grade glioma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01887522"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01173679"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000209","diseaseName":"T-cell acute lymphoblastic leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02538926"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005301","diseaseName":"multiple sclerosis","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03674099"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015686","diseaseName":"primary peritoneal carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00928642"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000497","diseaseName":"fibromatosis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02495519","https://clinicaltrials.gov/study/NCT01137916"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01196741","https://clinicaltrials.gov/study/NCT00610714"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0006861","diseaseName":"male breast carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00559507"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001951","diseaseName":"colorectal carcinoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03844620"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0005774","diseaseName":"brain disease","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02661113"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003893","diseaseName":"ovarian neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02736305"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0006861","diseaseName":"male breast carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00045188"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02638428"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00237172","https://clinicaltrials.gov/study/NCT00867113","https://clinicaltrials.gov/study/NCT01483014","https://clinicaltrials.gov/study/NCT00237185","https://clinicaltrials.gov/study/NCT00025246","https://clinicaltrials.gov/study/NCT01172548","https://clinicaltrials.gov/study/NCT02712112","https://clinicaltrials.gov/study/NCT00112632","https://clinicaltrials.gov/study/NCT01267695","https://clinicaltrials.gov/study/NCT00028002","https://clinicaltrials.gov/study/NCT00455559","https://clinicaltrials.gov/study/NCT00500188"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001961","diseaseName":"intrahepatic cholangiocarcinoma","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05535647"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004979","diseaseName":"asthma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01097694"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03352427"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03704688","https://clinicaltrials.gov/study/NCT01813734"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002676","diseaseName":"adult fibrosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00084630"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000574","diseaseName":"lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02874404"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00027586"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00500110","https://clinicaltrials.gov/study/NCT00251225","https://clinicaltrials.gov/study/NCT00084825","https://clinicaltrials.gov/study/NCT00080678","https://clinicaltrials.gov/study/NCT00427999"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000673","diseaseName":"prostate adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01316458"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000181","diseaseName":"head and neck squamous cell carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01488318"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04416750"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01267266"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003968","diseaseName":"angiosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02048722"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02080260"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01051115"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT04284202"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05159245","https://clinicaltrials.gov/study/NCT02925234","https://clinicaltrials.gov/study/NCT06246643"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03657641","https://clinicaltrials.gov/study/NCT04450836","https://clinicaltrials.gov/study/NCT02023333","https://clinicaltrials.gov/study/NCT04660812","https://clinicaltrials.gov/study/NCT03828799"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02925234","https://clinicaltrials.gov/study/NCT04116541","https://clinicaltrials.gov/study/NCT05159245"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00754325","https://clinicaltrials.gov/study/NCT00410813","https://clinicaltrials.gov/study/NCT00546104","https://clinicaltrials.gov/study/NCT00696072","https://clinicaltrials.gov/study/NCT00767520"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005149","diseaseName":"pulmonary hypertension","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00583115"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01690065"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02167256"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01641107"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011934","diseaseName":"dermatofibrosarcoma protuberans","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00243191","https://clinicaltrials.gov/study/NCT00084630"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04704154"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00551252"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002617","diseaseName":"metastatic melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00881049"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00594555"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04578847","https://clinicaltrials.gov/study/NCT01698905","https://clinicaltrials.gov/study/NCT03874858","https://clinicaltrials.gov/study/NCT04147533","https://clinicaltrials.gov/study/NCT03906292","https://clinicaltrials.gov/study/NCT02917720","https://clinicaltrials.gov/study/NCT03654768","https://clinicaltrials.gov/study/NCT04126681","https://clinicaltrials.gov/study/NCT01784068"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06119789"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006475","https://clinicaltrials.gov/study/NCT00955916","https://clinicaltrials.gov/study/NCT00250042","https://clinicaltrials.gov/study/NCT01319981","https://clinicaltrials.gov/study/NCT00110058","https://clinicaltrials.gov/study/NCT00769327","https://clinicaltrials.gov/study/NCT00038610","https://clinicaltrials.gov/study/NCT00006053","https://clinicaltrials.gov/study/NCT00045422","https://clinicaltrials.gov/study/NCT00618501","https://clinicaltrials.gov/study/NCT00509093","https://clinicaltrials.gov/study/NCT00458848","https://clinicaltrials.gov/study/NCT00006052","https://clinicaltrials.gov/study/NCT01092741","https://clinicaltrials.gov/study/NCT00982488"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000760","diseaseName":"malignant peripheral nerve sheath tumor","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00427583"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02272998"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0016216","diseaseName":"adult hepatocellular carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00459108"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02906696","https://clinicaltrials.gov/study/NCT04793399"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02742090"]},{"drugId":"CHEMBL4130229","drugName":"VODOBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005180","diseaseName":"Parkinson disease","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03655236"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT04310709"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015686","diseaseName":"primary peritoneal carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0013730","diseaseName":"graft versus host disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702689","https://clinicaltrials.gov/study/NCT02891395"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01804985","https://clinicaltrials.gov/study/NCT01690065","https://clinicaltrials.gov/study/NCT02001818"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00031915","https://clinicaltrials.gov/study/NCT00062205","https://clinicaltrials.gov/study/NCT00085475","https://clinicaltrials.gov/study/NCT00090987"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001814","diseaseName":"nephrogenic fibrosing dermopathy","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00677092"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002158","diseaseName":"fallopian tube cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039585"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018076","diseaseName":"tuberculosis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03891901"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00112775","https://clinicaltrials.gov/study/NCT01005758","https://clinicaltrials.gov/study/NCT01227135"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00161213"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01011075","https://clinicaltrials.gov/study/NCT01083589"]},{"drugId":"CHEMBL4130229","drugName":"VODOBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"HP_0000726","diseaseName":"Dementia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03996460"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000654","diseaseName":"childhood cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04733534"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000096","diseaseName":"neoplasm of mature B-cells","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03364231"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT05554341"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01028222","https://clinicaltrials.gov/study/NCT00788775"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005543","diseaseName":"glioma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01140568"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02287727","https://clinicaltrials.gov/study/NCT05900648"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01685125"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004198","diseaseName":"skin neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00027586"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019457","diseaseName":"therapy related acute myeloid leukemia and myelodysplastic syndrome","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01238211"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00149136"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002367","diseaseName":"kidney cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00323791"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02113319"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02425683"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0006859","diseaseName":"head and neck malignant neoplasia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00045669"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000729","diseaseName":"loiasis","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02644525"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02478164"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03555149","https://clinicaltrials.gov/study/NCT02581059","https://clinicaltrials.gov/study/NCT03099486"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039377"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002087","diseaseName":"peritoneum cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00036751","https://clinicaltrials.gov/study/NCT00039585"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009907","diseaseName":"Desmoid-type fibromatosis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00928525"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05594784"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04051606"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00780676","https://clinicaltrials.gov/study/NCT05198843","https://clinicaltrials.gov/study/NCT00817531"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01312818"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000685","diseaseName":"rheumatoid arthritis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00154336"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02888990","https://clinicaltrials.gov/study/NCT00391989","https://clinicaltrials.gov/study/NCT01724879","https://clinicaltrials.gov/study/NCT03023046","https://clinicaltrials.gov/study/NCT00390793","https://clinicaltrials.gov/study/NCT01310010","https://clinicaltrials.gov/study/NCT01256398","https://clinicaltrials.gov/study/NCT00720109","https://clinicaltrials.gov/study/NCT01004497"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0013730","diseaseName":"graft versus host disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02891395"]},{"drugId":"CHEMBL206834","drugName":"BAFETINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01144260"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002087","diseaseName":"peritoneum cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00039585","https://clinicaltrials.gov/study/NCT00036751"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00570401"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03364231"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001951","diseaseName":"colorectal carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02368886"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02925234","https://clinicaltrials.gov/study/NCT02029001","https://clinicaltrials.gov/study/NCT04449549"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03919175"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02303899"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00222144","https://clinicaltrials.gov/study/NCT00193349","https://clinicaltrials.gov/study/NCT00425646","https://clinicaltrials.gov/study/NCT00248482"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01771458"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00918385","https://clinicaltrials.gov/study/NCT00860158"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00323362"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0008550","diseaseName":"Hepatobiliary Neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02265341"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02272998"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00895297","https://clinicaltrials.gov/study/NCT02709083","https://clinicaltrials.gov/study/NCT00320190"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02926222"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0024686","diseaseName":"tenosynovial giant cell tumor, diffuse type","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01207492"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02709083","https://clinicaltrials.gov/study/NCT01866553","https://clinicaltrials.gov/study/NCT00644878"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004979","diseaseName":"asthma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04129931"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000044","diseaseName":"pancreatic adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00735917"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT05134532","https://clinicaltrials.gov/study/NCT05773105","https://clinicaltrials.gov/study/NCT04696055","https://clinicaltrials.gov/study/NCT04718909","https://clinicaltrials.gov/study/NCT04170556"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00041340"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002914","diseaseName":"uterine sarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00075400"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02420717","https://clinicaltrials.gov/study/NCT02043587"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT05900648"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00544908"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00054431","https://clinicaltrials.gov/study/NCT00510926","https://clinicaltrials.gov/study/NCT01003054","https://clinicaltrials.gov/study/NCT00030394","https://clinicaltrials.gov/study/NCT00511303","https://clinicaltrials.gov/study/NCT00171158","https://clinicaltrials.gov/study/NCT01593254","https://clinicaltrials.gov/study/NCT00852566","https://clinicaltrials.gov/study/NCT00103844","https://clinicaltrials.gov/study/NCT00048672","https://clinicaltrials.gov/study/NCT00514969","https://clinicaltrials.gov/study/NCT00219752","https://clinicaltrials.gov/study/NCT00858806","https://clinicaltrials.gov/study/NCT00219726","https://clinicaltrials.gov/study/NCT00049192","https://clinicaltrials.gov/study/NCT02269267","https://clinicaltrials.gov/study/NCT01216085","https://clinicaltrials.gov/study/NCT00171223"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00477269"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02538926"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03269669"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02085603"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01887561","https://clinicaltrials.gov/study/NCT01627132","https://clinicaltrials.gov/study/NCT01804985","https://clinicaltrials.gov/study/NCT02268370","https://clinicaltrials.gov/study/NCT01802450"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000389","diseaseName":"cutaneous melanoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02587650"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00161213"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02750514"]},{"drugId":"CHEMBL3678958","drugName":"RUSERONTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT04015024"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00892177"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00684411"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0002691","diseaseName":"liver cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00459108"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011705","diseaseName":"lymphangioleiomyomatosis","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02737202"]},{"drugId":"CHEMBL4130229","drugName":"VODOBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02629692"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001361","diseaseName":"localised scleroderma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00479934"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"HP_0001880","diseaseName":"Eosinophilia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00230334"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0100096","diseaseName":"COVID-19","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04346147"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015686","diseaseName":"primary peritoneal carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02278783"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02638766","https://clinicaltrials.gov/study/NCT02606097","https://clinicaltrials.gov/study/NCT02889328","https://clinicaltrials.gov/study/NCT01068769"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004979","diseaseName":"asthma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04129931"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005180","diseaseName":"Parkinson disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03205488"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0020547","diseaseName":"chronic graft versus host disease","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01898377"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01900743"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000702","diseaseName":"small cell lung carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01935336"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001361","diseaseName":"pulmonary arterial hypertension","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01179737"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00510653","https://clinicaltrials.gov/study/NCT00928642","https://clinicaltrials.gov/study/NCT00216112","https://clinicaltrials.gov/study/NCT00039585"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003865","diseaseName":"acral lentiginous melanoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01395121"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02297139"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05370807"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00559507"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002158","diseaseName":"fallopian tube cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01196741"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00782834"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00594555"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02947893"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01761747"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00397878"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005149","diseaseName":"pulmonary hypertension","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00583115"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00219752","https://clinicaltrials.gov/study/NCT00049192","https://clinicaltrials.gov/study/NCT00511303","https://clinicaltrials.gov/study/NCT00048672","https://clinicaltrials.gov/study/NCT00171223","https://clinicaltrials.gov/study/NCT01003054","https://clinicaltrials.gov/study/NCT00030394","https://clinicaltrials.gov/study/NCT00219726","https://clinicaltrials.gov/study/NCT00054431","https://clinicaltrials.gov/study/NCT00171158"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1002001","diseaseName":"core binding factor acute myeloid leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01238211"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005540","diseaseName":"bile duct carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02115542"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02425683"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00038649","https://clinicaltrials.gov/study/NCT02709083","https://clinicaltrials.gov/study/NCT00320190","https://clinicaltrials.gov/study/NCT00415909","https://clinicaltrials.gov/study/NCT00058747","https://clinicaltrials.gov/study/NCT00210119","https://clinicaltrials.gov/study/NCT00114959"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00844298","https://clinicaltrials.gov/study/NCT00809211","https://clinicaltrials.gov/study/NCT00769327"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01395017","https://clinicaltrials.gov/study/NCT00474812","https://clinicaltrials.gov/study/NCT01652976"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05130021"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05725200"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03690115","https://clinicaltrials.gov/study/NCT04188405"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00323362"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000637","diseaseName":"osteosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02048371"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05306301","https://clinicaltrials.gov/study/NCT06061094","https://clinicaltrials.gov/study/NCT04747912","https://clinicaltrials.gov/study/NCT04475731","https://clinicaltrials.gov/study/NCT05268003"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00613171","https://clinicaltrials.gov/study/NCT00555581","https://clinicaltrials.gov/study/NCT00479934"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001471","diseaseName":"Merkel cell skin cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00068783"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02742090"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"HP_0001880","diseaseName":"Eosinophilia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00230334"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00290485"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000658","diseaseName":"plexiform neurofibroma","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT03688568"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001919","diseaseName":"Spinal cord injury","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02363361"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015277","diseaseName":"medullary thyroid gland carcinoma","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT03838692"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000209","diseaseName":"T-cell acute lymphoblastic leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02538926"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02467270","https://clinicaltrials.gov/study/NCT04188405","https://clinicaltrials.gov/study/NCT04160546","https://clinicaltrials.gov/study/NCT04070443","https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000768","diseaseName":"idiopathic pulmonary fibrosis","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00131274"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02538926"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01782508"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01874665"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02241720"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000873","diseaseName":"lymphoblastic lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023046"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000183","diseaseName":"Hodgkins lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03776864"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02925234"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT00070499","https://clinicaltrials.gov/study/NCT04147533","https://clinicaltrials.gov/study/NCT03906292","https://clinicaltrials.gov/study/NCT02689440","https://clinicaltrials.gov/study/NCT04126681","https://clinicaltrials.gov/study/NCT03654768","https://clinicaltrials.gov/study/NCT04578847","https://clinicaltrials.gov/study/NCT03193281","https://clinicaltrials.gov/study/NCT00254423"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005221","diseaseName":"cholangiocarcinoma","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02162914"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004198","diseaseName":"skin neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00027586"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05638763","https://clinicaltrials.gov/study/NCT04838041","https://clinicaltrials.gov/study/NCT05007873","https://clinicaltrials.gov/study/NCT04626024","https://clinicaltrials.gov/study/NCT03573596"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000637","diseaseName":"osteosarcoma","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04803877"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002676","diseaseName":"adult fibrosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00084630"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000574","diseaseName":"lymphoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00882206"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0008550","diseaseName":"Hepatobiliary Neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02265341"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01410708"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0015686","diseaseName":"primary peritoneal carcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01196741"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0013730","diseaseName":"graft versus host disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702689","https://clinicaltrials.gov/study/NCT02891395"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00171938","https://clinicaltrials.gov/study/NCT00290771"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0024880","diseaseName":"metastatic malignant neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00084825","https://clinicaltrials.gov/study/NCT00080678"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002914","diseaseName":"uterine sarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00075400"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000574","diseaseName":"lymphoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02874404"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06336395"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03207256"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01929616","https://clinicaltrials.gov/study/NCT02788006","https://clinicaltrials.gov/study/NCT02368886"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018975","diseaseName":"neurofibromatosis type 1","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01673009"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00110058","https://clinicaltrials.gov/study/NCT00045422","https://clinicaltrials.gov/study/NCT00006053","https://clinicaltrials.gov/study/NCT00006475","https://clinicaltrials.gov/study/NCT00509093","https://clinicaltrials.gov/study/NCT00038610","https://clinicaltrials.gov/study/NCT00458848","https://clinicaltrials.gov/study/NCT00618501","https://clinicaltrials.gov/study/NCT01092741","https://clinicaltrials.gov/study/NCT00006052","https://clinicaltrials.gov/study/NCT00769327","https://clinicaltrials.gov/study/NCT00955916"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000503","diseaseName":"gastric adenocarcinoma","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00209079"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00425646","https://clinicaltrials.gov/study/NCT00222144","https://clinicaltrials.gov/study/NCT00248482"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00504153"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00338728","https://clinicaltrials.gov/study/NCT00087152","https://clinicaltrials.gov/study/NCT00193180"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00323063"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT04327700"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06368414"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000764","diseaseName":"HIV infection","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05780073"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0007444","diseaseName":"Plasmodium falciparum malaria","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03697668"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04188405","https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001814","diseaseName":"nephrogenic fibrosing dermopathy","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00677092"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000333","diseaseName":"chondrosarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00928525"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00062205","https://clinicaltrials.gov/study/NCT00090987","https://clinicaltrials.gov/study/NCT00031915","https://clinicaltrials.gov/study/NCT00085475"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":2,"status":"Suspended","source":["https://clinicaltrials.gov/study/NCT01222013"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01424982"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05385549"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03807479"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01221376","https://clinicaltrials.gov/study/NCT01804985","https://clinicaltrials.gov/study/NCT01503502","https://clinicaltrials.gov/study/NCT03241199","https://clinicaltrials.gov/study/NCT02001818","https://clinicaltrials.gov/study/NCT02687425","https://clinicaltrials.gov/study/NCT00146913"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003060","diseaseName":"biliary tract cancer","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04492033"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00397878"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001512","diseaseName":"endometrial carcinoma","phase":2,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05564377"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0002087","diseaseName":"peritoneum cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00672295"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002617","diseaseName":"metastatic melanoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00597038"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0000873","diseaseName":"lymphoblastic lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000305","diseaseName":"breast carcinoma","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03854903"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003956","diseaseName":"seasonal allergic rhinitis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00426179"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02910843"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0016216","diseaseName":"adult hepatocellular carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00045604","https://clinicaltrials.gov/study/NCT00052494"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0009937","diseaseName":"pulmonary venoocclusive disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00891527"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001993","diseaseName":"scleroderma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00764309"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01216176"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001465","diseaseName":"gliosarcoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00609999"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000211","diseaseName":"unspecified peripheral T-cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02225574"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01046487","https://clinicaltrials.gov/study/NCT00026169","https://clinicaltrials.gov/study/NCT00611689"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02829840"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000350","diseaseName":"Malignant Bone Neoplasm","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05830084"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"HP_0100543","diseaseName":"Cognitive impairment","phase":1,"status":"Enrolling by invitation","source":["https://clinicaltrials.gov/study/NCT02921477"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000870","diseaseName":"childhood acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702403"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011705","diseaseName":"lymphangioleiomyomatosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03131999"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001936","diseaseName":"adult T acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002918","diseaseName":"rhabdomyosarcoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03041701"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00444015","https://clinicaltrials.gov/study/NCT00826449","https://clinicaltrials.gov/study/NCT01999985"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02819804"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00501410"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01864655"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01498445"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002617","diseaseName":"metastatic melanoma","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04903119"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001946","diseaseName":"childhood B acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00074308"]},{"drugId":"CHEMBL495727","drugName":"AT-9283","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00443976"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000389","diseaseName":"cutaneous melanoma","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02812693"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":1,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06283303","https://clinicaltrials.gov/study/NCT04008511","https://clinicaltrials.gov/study/NCT06283134"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02389309"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00667953"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01426334","https://clinicaltrials.gov/study/NCT02047149","https://clinicaltrials.gov/study/NCT00500006"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00080665"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007739","diseaseName":"Huntington disease","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03764215"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000641","diseaseName":"papillary thyroid carcinoma","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03469011"]},{"drugId":"CHEMBL3545085","drugName":"XL-228","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000574","diseaseName":"lymphoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00526838"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001376","diseaseName":"synovial sarcoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01281865"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011705","diseaseName":"lymphangioleiomyomatosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02116712"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00219765","https://clinicaltrials.gov/study/NCT00101088"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00162214"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05495035"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009907","diseaseName":"Desmoid-type fibromatosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00287846"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04835584"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00074308"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001947","diseaseName":"childhood T acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002430","diseaseName":"primary myelofibrosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00088231"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03347292"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00088231"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001935","diseaseName":"adult B acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001947","diseaseName":"childhood T acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0044903","diseaseName":"myelofibrosis","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02493530"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03305913","https://clinicaltrials.gov/study/NCT01896856","https://clinicaltrials.gov/study/NCT03081494"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000198","diseaseName":"myelodysplastic syndrome","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02923986"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0005774","diseaseName":"brain disease","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00895960"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000183","diseaseName":"Hodgkins lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766","https://clinicaltrials.gov/study/NCT02164006"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00028847"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001378","diseaseName":"multiple myeloma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00560352","https://clinicaltrials.gov/study/NCT01643603"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00021229"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03042689"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00038194"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0009441","diseaseName":"Waldenstrom macroglobulinemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT04115059"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000211","diseaseName":"unspecified peripheral T-cell lymphoma","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05559008"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT04655391"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002918","diseaseName":"rhabdomyosarcoma","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04625907"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02081378","https://clinicaltrials.gov/study/NCT02779283","https://clinicaltrials.gov/study/NCT00940524"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002974","diseaseName":"cervical cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011382","diseaseName":"sickle cell anemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03997903"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02081378"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00869401"]},{"drugId":"CHEMBL495727","drugName":"AT-9283","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00985868"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011705","diseaseName":"lymphangioleiomyomatosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03131999"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000550","diseaseName":"Splenic Marginal Zone Lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000198","diseaseName":"myelodysplastic syndrome","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02829840"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766","https://clinicaltrials.gov/study/NCT02100852","https://clinicaltrials.gov/study/NCT02006485"]},{"drugId":"CHEMBL1908397","drugName":"KW-2449","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00779480"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702403"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01735968","https://clinicaltrials.gov/study/NCT01275222","https://clinicaltrials.gov/study/NCT03609424","https://clinicaltrials.gov/study/NCT00441155","https://clinicaltrials.gov/study/NCT02257541","https://clinicaltrials.gov/study/NCT00006357","https://clinicaltrials.gov/study/NCT04006769","https://clinicaltrials.gov/study/NCT00135005","https://clinicaltrials.gov/study/NCT01468688"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03283137","https://clinicaltrials.gov/study/NCT02268851","https://clinicaltrials.gov/study/NCT03671590"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00183833"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000191","diseaseName":"MALT lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT04063124"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0000870","diseaseName":"childhood acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02819804"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02116894","https://clinicaltrials.gov/study/NCT03215264"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01826838"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000183","diseaseName":"Hodgkins lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766","https://clinicaltrials.gov/study/NCT02164006"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007576","diseaseName":"esophageal cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00324077","https://clinicaltrials.gov/study/NCT02923986"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003833","diseaseName":"brain neoplasm","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02389309"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00195260","https://clinicaltrials.gov/study/NCT01001936"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05432518"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000198","diseaseName":"myelodysplastic syndrome","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00892190"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0001852","diseaseName":"small intestine lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019471","diseaseName":"adult T-cell leukemia/lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0018906","diseaseName":"follicular lymphoma","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT05152459"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000403","diseaseName":"diffuse large B-cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000183","diseaseName":"Hodgkins lymphoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01643603"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL3545085","drugName":"XL-228","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00526838"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000094","diseaseName":"B-cell acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000956","diseaseName":"small intestine cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01660971"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000673","diseaseName":"prostate adenocarcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00861471"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01271166"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05993949"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0009937","diseaseName":"pulmonary venoocclusive disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00891527"]},{"drugId":"CHEMBL1738757","drugName":"REBASTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00827138"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007079","diseaseName":"alcohol dependence","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02262026"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03475251","https://clinicaltrials.gov/study/NCT02095054"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":1,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02431403"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02253277","https://clinicaltrials.gov/study/NCT01220648","https://clinicaltrials.gov/study/NCT01456676","https://clinicaltrials.gov/study/NCT01702064","https://clinicaltrials.gov/study/NCT02081378","https://clinicaltrials.gov/study/NCT00702403","https://clinicaltrials.gov/study/NCT01223898"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019469","diseaseName":"T-cell large granular lymphocyte leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02923986","https://clinicaltrials.gov/study/NCT02680951","https://clinicaltrials.gov/study/NCT03560908"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03379051"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00402766"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":1,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05426811"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT04126707","https://clinicaltrials.gov/study/NCT03882281"]},{"drugId":"CHEMBL495727","drugName":"AT-9283","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01431664"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004142","diseaseName":"colorectal neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00934882"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01306942","https://clinicaltrials.gov/study/NCT00820170","https://clinicaltrials.gov/study/NCT00924352","https://clinicaltrials.gov/study/NCT00452673"]},{"drugId":"CHEMBL1201740","drugName":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04205903"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002715","diseaseName":"uterine cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00506779"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0810000","diseaseName":"choroidal neovascularization","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00403156"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000131","diseaseName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02782403"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02494882"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01188889","https://clinicaltrials.gov/study/NCT00324077"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004329","diseaseName":"alcohol drinking","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02732587"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00829647","https://clinicaltrials.gov/study/NCT00872976"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00717704","https://clinicaltrials.gov/study/NCT00339144","https://clinicaltrials.gov/study/NCT00099606","https://clinicaltrials.gov/study/NCT00429234","https://clinicaltrials.gov/study/NCT01445509","https://clinicaltrials.gov/study/NCT00388427","https://clinicaltrials.gov/study/NCT00495872","https://clinicaltrials.gov/study/NCT00662636"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000785","diseaseName":"Sezary's disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00401024","https://clinicaltrials.gov/study/NCT00010049","https://clinicaltrials.gov/study/NCT00387933","https://clinicaltrials.gov/study/NCT00354068"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00053248","https://clinicaltrials.gov/study/NCT00268229","https://clinicaltrials.gov/study/NCT00004932","https://clinicaltrials.gov/study/NCT00244829","https://clinicaltrials.gov/study/NCT00081133","https://clinicaltrials.gov/study/NCT00686218","https://clinicaltrials.gov/study/NCT00301093","https://clinicaltrials.gov/study/NCT00258271","https://clinicaltrials.gov/study/NCT00066326","https://clinicaltrials.gov/study/NCT00064285","https://clinicaltrials.gov/study/NCT00093639","https://clinicaltrials.gov/study/NCT00061945","https://clinicaltrials.gov/study/NCT00015860"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0810000","diseaseName":"choroidal neovascularization","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT00403156"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00826449","https://clinicaltrials.gov/study/NCT01999985"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000691","diseaseName":"sarcoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019474","diseaseName":"hepatosplenic T-cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL3545085","drugName":"XL-228","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00464113"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05623774"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00949988"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":1,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02954523"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000349","diseaseName":"clear cell renal carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00193258"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008978","diseaseName":"chordoma","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01407198"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT02379416"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01643603"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000044","diseaseName":"pancreatic adenocarcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00598091"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00506831"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000588","diseaseName":"mesothelioma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00402766"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005149","diseaseName":"pulmonary hypertension","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT01568645"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02081378","https://clinicaltrials.gov/study/NCT02011945","https://clinicaltrials.gov/study/NCT00482703","https://clinicaltrials.gov/study/NCT00337454","https://clinicaltrials.gov/study/NCT05640804"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04835584"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00080665"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00483366","https://clinicaltrials.gov/study/NCT00084513","https://clinicaltrials.gov/study/NCT00253565"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02268851","https://clinicaltrials.gov/study/NCT03283137"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02006485","https://clinicaltrials.gov/study/NCT01767766"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001951","diseaseName":"colorectal carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02199223"]},{"drugId":"CHEMBL1738757","drugName":"REBASTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000304","diseaseName":"breast adenocarcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02824575"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001469","diseaseName":"Mantle cell lymphoma","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02268851"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0020547","diseaseName":"chronic graft versus host disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01810718"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00021229"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001469","diseaseName":"Mantle cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00441155","https://clinicaltrials.gov/study/NCT00135005","https://clinicaltrials.gov/study/NCT01468688","https://clinicaltrials.gov/study/NCT01735968","https://clinicaltrials.gov/study/NCT02257541","https://clinicaltrials.gov/study/NCT00006357","https://clinicaltrials.gov/study/NCT04006769"]},{"drugId":"CHEMBL1738757","drugName":"REBASTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000305","diseaseName":"breast carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02824575"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003032","diseaseName":"anaplastic large cell lymphoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02462538"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00601510"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01222143"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02779283","https://clinicaltrials.gov/study/NCT00892190","https://clinicaltrials.gov/study/NCT00850382","https://clinicaltrials.gov/study/NCT04580121"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02779283"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00573404"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000895","diseaseName":"desmoplastic small round cell tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00417807"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000044","diseaseName":"pancreatic adenocarcinoma","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01660971"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00281996"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02779283"]},{"drugId":"CHEMBL3545085","drugName":"XL-228","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00464113"]},{"drugId":"CHEMBL217092","drugName":"SARACATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00475956","https://clinicaltrials.gov/study/NCT00496028","https://clinicaltrials.gov/study/NCT00704366"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00281996"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05623774"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02001909","https://clinicaltrials.gov/study/NCT01117623","https://clinicaltrials.gov/study/NCT04200404","https://clinicaltrials.gov/study/NCT01287598","https://clinicaltrials.gov/study/NCT01339104","https://clinicaltrials.gov/study/NCT03406871","https://clinicaltrials.gov/study/NCT01322438","https://clinicaltrials.gov/study/NCT01853046","https://clinicaltrials.gov/study/NCT01973868","https://clinicaltrials.gov/study/NCT00960258","https://clinicaltrials.gov/study/NCT02466802","https://clinicaltrials.gov/study/NCT01096030","https://clinicaltrials.gov/study/NCT02106845"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000870","diseaseName":"childhood acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702403"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03946917"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000158","diseaseName":"Central Nervous System Neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00401024","https://clinicaltrials.gov/study/NCT00010049","https://clinicaltrials.gov/study/NCT00354068","https://clinicaltrials.gov/study/NCT00387933"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0009441","diseaseName":"Waldenstrom macroglobulinemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000768","diseaseName":"idiopathic pulmonary fibrosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02874989"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000211","diseaseName":"unspecified peripheral T-cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000183","diseaseName":"Hodgkins lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004976","diseaseName":"amyotrophic lateral sclerosis","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04744532"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04205903"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03292783"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000309","diseaseName":"Burkitts lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0006859","diseaseName":"head and neck malignant neoplasia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05816785"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0044881","diseaseName":"hematopoietic and lymphoid cell neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02352558"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00183833"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00135005","https://clinicaltrials.gov/study/NCT00441155"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0001378","diseaseName":"multiple myeloma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00560391"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001422","diseaseName":"cirrhosis of liver","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT05224128"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001946","diseaseName":"childhood B acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000181","diseaseName":"head and neck squamous cell carcinoma","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05816785"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00920868"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004110","diseaseName":"refractory hairy cell leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002429","diseaseName":"polycythemia vera","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02493530"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000094","diseaseName":"B-cell acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02815059"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03747679","https://clinicaltrials.gov/study/NCT01374139"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000657","diseaseName":"rectum cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019465","diseaseName":"nodal marginal zone B-cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011962","diseaseName":"endometrial cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000198","diseaseName":"myelodysplastic syndrome","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01643603"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702403","https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019472","diseaseName":"extranodal nasal NK/T cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0044903","diseaseName":"myelofibrosis","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02493530"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000956","diseaseName":"small intestine cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL3678958","drugName":"RUSERONTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05445154"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01643603"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002586","diseaseName":"thymus cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008315","diseaseName":"prostate cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00038194"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00093639","https://clinicaltrials.gov/study/NCT00301093","https://clinicaltrials.gov/study/NCT00015860","https://clinicaltrials.gov/study/NCT00053248","https://clinicaltrials.gov/study/NCT00061945","https://clinicaltrials.gov/study/NCT00004932","https://clinicaltrials.gov/study/NCT00686218","https://clinicaltrials.gov/study/NCT00081133","https://clinicaltrials.gov/study/NCT00064285","https://clinicaltrials.gov/study/NCT00066326","https://clinicaltrials.gov/study/NCT00268229","https://clinicaltrials.gov/study/NCT01126814","https://clinicaltrials.gov/study/NCT00244829","https://clinicaltrials.gov/study/NCT00258271"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02268435"]},{"drugId":"CHEMBL4130229","drugName":"VODOBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005180","diseaseName":"Parkinson disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02970019"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002087","diseaseName":"peritoneum cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01218477","https://clinicaltrials.gov/study/NCT00345826","https://clinicaltrials.gov/study/NCT00064233","https://clinicaltrials.gov/study/NCT00306202","https://clinicaltrials.gov/study/NCT00816283","https://clinicaltrials.gov/study/NCT00978731"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011382","diseaseName":"sickle cell anemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT03997903"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000095","diseaseName":"chronic lymphocytic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766","https://clinicaltrials.gov/study/NCT02535286","https://clinicaltrials.gov/study/NCT02006485","https://clinicaltrials.gov/study/NCT02100852"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002108","diseaseName":"thyroid cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00354523"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00088231","https://clinicaltrials.gov/study/NCT00047502","https://clinicaltrials.gov/study/NCT00015834","https://clinicaltrials.gov/study/NCT00040105","https://clinicaltrials.gov/study/NCT00702403","https://clinicaltrials.gov/study/NCT01795716"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0007444","diseaseName":"Plasmodium falciparum malaria","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02614404"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002430","diseaseName":"primary myelofibrosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00088231"]},{"drugId":"CHEMBL2316582","drugName":"OLVEREMBATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05495035"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0005575","diseaseName":"colorectal cancer","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06200363"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02081378"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000702","diseaseName":"small cell lung carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01187615"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0004289","diseaseName":"lymphoid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000581","diseaseName":"Thymoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02164240"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000218","diseaseName":"Digestive System Carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02386397"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008903","diseaseName":"lung cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00052494","https://clinicaltrials.gov/study/NCT00045604"]},{"drugId":"CHEMBL3948730","drugName":"UMBRALISIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002429","diseaseName":"polycythemia vera","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02493530"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003060","diseaseName":"non-small cell lung carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00787852"]},{"drugId":"CHEMBL4208229","drugName":"ASCIMINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0003086","diseaseName":"kidney disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03605277"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0006859","diseaseName":"head and neck malignant neoplasia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00882583"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05644392"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0008978","diseaseName":"chordoma","phase":1,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT01175109"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000196","diseaseName":"metastatic prostate cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00439270"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01383447"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT06095375"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00905398"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05245968"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02081378","https://clinicaltrials.gov/study/NCT00702403","https://clinicaltrials.gov/study/NCT00088231","https://clinicaltrials.gov/study/NCT00040105","https://clinicaltrials.gov/study/NCT02480608","https://clinicaltrials.gov/study/NCT00428909","https://clinicaltrials.gov/study/NCT01795716","https://clinicaltrials.gov/study/NCT00047502","https://clinicaltrials.gov/study/NCT00015834"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1001051","diseaseName":"mycosis fungoides","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02168777"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000209","diseaseName":"T-cell acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00088231"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004643","diseaseName":"myeloid leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01643603"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0007576","diseaseName":"esophageal cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02574663"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000519","diseaseName":"glioblastoma multiforme","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00948389","https://clinicaltrials.gov/study/NCT00895960"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002108","diseaseName":"thyroid cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00354523"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000756","diseaseName":"melanoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00667953"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00219765","https://clinicaltrials.gov/study/NCT00101088"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0002158","diseaseName":"fallopian tube cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00672295"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002618","diseaseName":"pancreatic carcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01025570"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001469","diseaseName":"Mantle cell lymphoma","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT02268851"]},{"drugId":"CHEMBL2105708","drugName":"PONATINIB HYDROCHLORIDE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02779283"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04872790","https://clinicaltrials.gov/study/NCT05523661"]},{"drugId":"CHEMBL3989869","drugName":"UMBRALISIB TOSYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0005952","diseaseName":"non-Hodgkins lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01767766","https://clinicaltrials.gov/study/NCT02006485"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011719","diseaseName":"gastrointestinal stromal tumor","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00573404"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00895128","https://clinicaltrials.gov/study/NCT01015222","https://clinicaltrials.gov/study/NCT01744652","https://clinicaltrials.gov/study/NCT00429234"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_1000026","diseaseName":"diffuse intrinsic pontine glioma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00996723","https://clinicaltrials.gov/study/NCT01644773"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02973711"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0008170","diseaseName":"ovarian cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00672295"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00762632"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001056","diseaseName":"gastric cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00601510"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0013730","diseaseName":"graft versus host disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00760981"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000673","diseaseName":"prostate adenocarcinoma","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00861471"]},{"drugId":"CHEMBL3678958","drugName":"RUSERONTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT05072522"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0004610","diseaseName":"acute lung injury","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03328117"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0000870","diseaseName":"childhood acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00702403"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00611689","https://clinicaltrials.gov/study/NCT00253565","https://clinicaltrials.gov/study/NCT00084513","https://clinicaltrials.gov/study/NCT00390156","https://clinicaltrials.gov/study/NCT00483366"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0001187","diseaseName":"urinary bladder cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03023319"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000770","diseaseName":"malignant pleural mesothelioma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00652574"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000209","diseaseName":"T-cell acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945"]},{"drugId":"CHEMBL3678958","drugName":"RUSERONTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT02859948"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00660920"]},{"drugId":"CHEMBL2095206","drugName":"BOSUTINIB MONOHYDRATE","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT04655391"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02439723"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000220","diseaseName":"acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03515200","https://clinicaltrials.gov/study/NCT00500006"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0011962","diseaseName":"endometrial cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00006357"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000389","diseaseName":"cutaneous melanoma","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02812693"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0002087","diseaseName":"fibrosarcoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00122473"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000359","diseaseName":"Malignant Pancreatic Neoplasm","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01048320"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0007254","diseaseName":"breast cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00903006"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0002715","diseaseName":"uterine cancer","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00506779"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0019457","diseaseName":"therapy related acute myeloid leukemia and myelodysplastic syndrome","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01876953"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021637","diseaseName":"low grade glioma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01884922"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000565","diseaseName":"leukemia","phase":1,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00028847"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0004992","diseaseName":"cancer","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01046487","https://clinicaltrials.gov/study/NCT00026169"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02829840"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01383447"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0009907","diseaseName":"Desmoid-type fibromatosis","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00287846"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000365","diseaseName":"colorectal adenocarcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00784446"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0000255","diseaseName":"angioimmunoblastic T-cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1000576","diseaseName":"Thymic Carcinoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00314873"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"EFO_0003032","diseaseName":"anaplastic large cell lymphoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00608361"]},{"drugId":"CHEMBL288441","drugName":"BOSUTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"HP_0000726","diseaseName":"Dementia","phase":1,"status":"Enrolling by invitation","source":["https://clinicaltrials.gov/study/NCT02921477"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0003541","diseaseName":"adult acute lymphoblastic leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00061945","https://clinicaltrials.gov/study/NCT00702403"]},{"drugId":"CHEMBL1171837","drugName":"PONATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000222","diseaseName":"acute myeloid leukemia","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02779283"]},{"drugId":"CHEMBL1642","drugName":"IMATINIB MESYLATE","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000717","diseaseName":"systemic scleroderma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00506831"]},{"drugId":"CHEMBL5314408","drugName":"AZD-0424","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000616","diseaseName":"neoplasm","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01668550"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0001376","diseaseName":"synovial sarcoma","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01281865"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000182","diseaseName":"hepatocellular carcinoma","phase":1,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05644379"]},{"drugId":"CHEMBL1946170","drugName":"REGORAFENIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_1001480","diseaseName":"metastatic colorectal cancer","phase":1,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03563157"]},{"drugId":"CHEMBL1421","drugName":"DASATINIB","type":"Small molecule","mechanismOfAction":"Bcr/Abl fusion protein","actionType":["Inhibitor"],"diseaseId":"MONDO_0011962","diseaseName":"endometrial cancer","phase":0.5,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01482728"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"MONDO_0021063","diseaseName":"malignant colon neoplasm","phase":0.5,"status":"Withdrawn","source":["https://clinicaltrials.gov/study/NCT02774512"]},{"drugId":"CHEMBL255863","drugName":"NILOTINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":0.5,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03228303"]},{"drugId":"CHEMBL941","drugName":"IMATINIB","type":"Small molecule","mechanismOfAction":"Tyrosine-protein kinase ABL inhibitor","actionType":["Inhibitor"],"diseaseId":"EFO_0000339","diseaseName":"chronic myelogenous leukemia","phase":0.5,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT03228303"]}]